fda warning letters glp-1 october 2025 news warnings against compounded GLP-1s raise the stakes for telehealths selling branded drugs 5 GMP Lessons from 2025's

That means a clinician should review whether a patient has a history of relevant endocrine issues, pancreatitis, gallbladder problems, kidney concerns, chronic GI symptoms, or other conditions that may affect safety or treatment choice

Your dose may need to go up as you progress through your treatment program

The Best GLP-1 Breakfast Foods When planning breakfast, aim for meals that are high in protein, rich in fiber, and include some healthy fats

The TRIUMPH-4 Phase 3 data provides the most current safety information: Nausea: 38.1% (9 mg) to 43.2% (12 mg) versus 10.7% placebo Diarrhea: 34.7% (9 mg) to 33.1% (12 mg) versus 13.4% placebo Constipation: 21.8% (9 mg) to 25.0% (12 mg) versus 8.7% placebo Vomiting: 20.4% (9 mg) to 20.9% (12 mg) versus 0% placebo Decreased appetite: 19.0% (9 mg) to 18.2% (12 mg) versus 9.4% placebo The pattern is clear

People who consume adequate protein (0.7 to 1.0 grams per pound of body weight daily) consistently achieve better body composition outcomes